图书馆订阅: Guest
生物医学工程评论综述™

每年出版 6 

ISSN 打印: 0278-940X

ISSN 在线: 1943-619X

SJR: 0.262 SNIP: 0.372 CiteScore™:: 2.2 H-Index: 56

Indexed in

Model-based Approaches to Biomarker Discovery and Evaluation: A Multidisciplinary Integrated Review

卷 30, 册 4-6, 2002, pp. 379-418
DOI: 10.1615/CritRevBiomedEng.v30.i456.60
Get accessGet access

摘要

The most common use of any mathematical or statistical model in physiology, pathophysiology, or therapy evaluation is to organize all relevant components characterizing the system behavior into a rigorously testable framework. This approach is widely applied both to the study of complex homeostatic paradigms involving endogenous substances and to the evaluation of the kinetics and dynamics of xenobiotics such as toxicants and drugs. In either case, one seeks a quantitative framework of the system that is consistent with known physiology and pharmacology and is "compatible" (in some meaningful sense) with all available data. The models are then evaluated and subjected to identifiability and validity tests and can then be used to estimate unknown parameters of interest, to make predictions about system behavior, to simulate previously unobserved behavior in response to a putative perturbation, and to aid in further experimental design. In a broader context, however, the focus and ultimate goal of this set of methodologies (whether this is explicitly stated or not) lies in understanding the mechanisms of physiology and pathophysiology and measuring the effect of therapeutic interventions through the accurate quantification of biomarkers of interest. In this review, we attempt to bring together under this comprehensive framework more than four decades of investigation on modeling and simulation in the life sciences (in particular, we will concentrate on the areas of pharmacology, physiology, and bioengineering). We demonstrate that such modeling approaches, when appropriately designed and evaluated, have significant potential and can be used to understand the multiple factors of disease progression and response to therapeutic interventions, the most likely causes of variability in population and individual responses to therapy, and the most appropriate timing of treatment administration. Lastly, they may allow estimation and prediction of significant outcomes in feasibility and clinical studies.

对本文的引用
  1. Vicini Paolo, Pharmacokinetics and Pharmacodynamics, in Encyclopedia of Medical Devices and Instrumentation, 2006. Crossref

  2. Zhang Liping, Sinha Vikram, Forgue S. Thomas, Callies Sophie, Ni Lan, Peck Richard, Allerheiligen Sandra R. B., Model-Based Drug Development: The Road to Quantitative Pharmacology, Journal of Pharmacokinetics and Pharmacodynamics, 33, 3, 2006. Crossref

  3. Vicini P, Multiscale Modeling in Drug Discovery and Development: Future Opportunities and Present Challenges, Clinical Pharmacology & Therapeutics, 88, 1, 2010. Crossref

  4. Roper Ryan T., Pia Saccomani Maria, Vicini Paolo, Cellular signaling identifiability analysis: A case study, Journal of Theoretical Biology, 264, 2, 2010. Crossref

  5. Hurwitz Selwyn J, Asif Ghazia, Schinazi Raymond F, Development of a Population Simulation Model for HIV Monotherapy Virological Outcomes Using Lamivudine, Antiviral Chemistry and Chemotherapy, 18, 6, 2007. Crossref

  6. Parker Robert S., Automation and Control in Biomedical Systems, in Springer Handbook of Automation, 2009. Crossref

Begell Digital Portal Begell 数字图书馆 电子图书 期刊 参考文献及会议录 研究收集 订购及政策 Begell House 联系我们 Language English 中文 Русский Português German French Spain